07/06
Headlines

OMER

Biotech Gainers: Cerus Corporation (NASDAQ:CERS), Omeros Corporation (NASDAQ:OMER), Durata Therapeutics Inc (NASDAQ:DRTX), Aastrom Biosciences Inc (NASDAQ:ASTM)

Adam Keintzel02 mins

Cerus Corporation (NASDAQ:CERS) and a pharmaceutical unit of Nipro Corporation announced a collaboration agreement. The collaboration will lead to the development of efficient and easy-to-use disposable kit for red cells. The project will benefit from the proprietary technology of Nipro towards the creation a red cell disposable kit that suits the needs of small and…

Read More

Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

Chris Lewis02 mins

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a fourth-quarter 2013 loss of 32 cents per share (excluding one-time expenses), narrower than the year-ago loss of 43 cents per share and the Zacks Consensus Estimate of a loss of 40 cents. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -6.08% in last session and finished the day at $1.70….

Read More

NASDAQ Losers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Himax Technologies, Inc. (NASDAQ:HIMX), Blue Earth Inc. (NASDAQ:BBLU), Omeros Corporation (NASDAQ:OMER), Net Element International Inc (NASDAQ:NETE)

Kristen Barton03 mins

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases, announced the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University…

Read More

Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

John Bellich03 mins

In June, Esperion Therapeutics Inc. (NASDAQ:ESPR), an Ann Arbor-based early-stage pharmaceutical company, raised $73 million in its IPO. It plans a secondary offering this year, based on trial results of its cholesterol-lowering drug. Esperion Therapeutics Inc (NASDAQ:ESPR) stock performance was -5.04% in last session and finished the day at $14.69. Traded volume was 31,400 shares…

Read More